CoChat
Sign Up
Cited by 195Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke ManagementVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.

Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation

Open access
Marinigh, Ricarda, Lane, Deirdre A., Lip, Gregory Y.H.·2011·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2010.12.013
Open this paper in CoChat — free accountOpen PDF

Abstract

The prevalence of atrial fibrillation (AF) in end-stage renal failure is high, with an increased risk of stroke among these patients with AF compared with the AF population without severe renal impairment. Many trials have shown the net clinical benefit of oral anticoagulation therapy for primary and secondary prevention of stroke in patient populations with AF. However, current stroke risk stratification schemes are based on studies that have deliberately excluded patients with severe renal impairment. Indeed, there are no large randomized controlled trials that assess the real risk/benefit of full intensity anticoagulation in patients with severe renal impairment. Also, rates of major bleeding episodes in anticoagulated hemodialysis patients with AF are high. These data are influenced by the lack of appropriate monitoring, the difficulties in maintaining the international normalized ratio target (variable between the studies), and an inaccurate bleeding classification. Thus, the limited available data may be difficult to apply to such a heterogeneous patient population, characterized by both an increased risk of bleeding and a hypercoagulability state, as seen in the patient population with severe renal impairment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2010.12.013

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. 2003, U.S. Renal Data System: USRDS 2002 Annual Data Report, Am J Kidney Dis, 41, S165
  2. Lip, 2011, Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk, Europace, 13, 145, 10.1093/europace/euq427 · DOI

Cited by

Sorted by citations

See all 195

Related

See all

Metadata

Authors
Marinigh, R., Lane, D. A., & Lip, G. Y. H.
Affiliations
  • University of Trieste (IT)
  • Birmingham City Hospital (GB)
Corresponding author
Lip, Gregory Y.H.
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2011-03
Volume
57
Issue
12
Pages
1339-1348
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2010.12.013
OpenAlex
W2163399076
Cited by
195
References
79
Citations by year
2026: 2 · 2024: 3 · 2023: 4 · 2022: 3 · 2021: 13 · 2020: 7 · 2019: 12 · 2018: 11 · 2017: 12 · 2016: 18 · 2015: 18 · 2014: 25 · 2013: 35 · 2012: 25
FWCI
4.98
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Funders
  • Bayer Healthcare
  • AstraZeneca
  • Boehringer
  • Bayer
  • Pfizer/BMS
  • Biotronic
  • Astellas
  • Sanofi
  • Cardiome
  • Merck
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
atrial fibrillation, severe renal impairment, end-stage renal disease, stroke prevention, oral anticoagulation, hemodialysis, major bleeding, stroke risk stratification, INR monitoring, hypercoagulability
MeSH terms
Algorithms, Anticoagulants, Atrial Fibrillation, Renal Dialysis, Hemorrhage, Humans, Kidney Failure, Chronic, Thromboembolism, Comorbidity, Risk Assessment, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review